Page 16 - FIMM_Brochure_2022
P. 16
FRIeMseMarch Groups
Computational Systems Medicine Genetic Epidemiology
Tero Aittokallio, FIMM Group Leader, Professor Jaakko Kaprio, Research Director, Professor
The group integrates computational and experimental The group investigates genetic and environmental deter-
approaches to model and predict complex relationships minants of common diseases and their behavioural risk
between genetic and functional dependencies and clinical factors using modern ‘omics approaches with the unique
phenotypes such as disease progression and treatment Finnish Twin Cohorts. The group focuses on traits with a
response. high relevance for public health, such as addiction, obesity,
mental health, physical activity, sleep and cognition.
Human Disease Genetics
Mark Daly, FIMM Director Cellular Genetics of Disease
Helena Kilpinen, Assistant Professor
The group builds and utilises genetic resources as a means
of articulating the causal pathways and processes under- The group studies cellular genetics and the cellular basis
lying human disease and for advancing the responsible use of developmental and other brain-related disorders, using
of genetics for clinical diagnostics and population health. human induced pluripotent stem cells as models, and
combining computational and experimental methods
Data Science - Genetic Epidemiology to study how genetic variation causes variability in cell
Andrea Ganna, FIMM-EMBL Group Leader phenotypes and contributes to differential susceptibility to
diseases.
The group develops and applies statistical and deep
learning approaches to combine disease trajectories and Individualised Therapies for Acute Leukaemia
genetic information from millions of individuals with the Mika Kontro, Group Leader
goal to improve public health interventions.
The group forecasts the treatment responses in acute my-
Translational Research and Personalised Medicine eloid leukaemia. The methods are developed in on-going
Caroline Heckman, Research Director prospective clinical trials to simultaneously validate their
full clinical significance.
The group focuses on understanding pathogenic and
drug resistance mechanisms and disease heterogeneity in Digital Diagnostics
haematological malignancies. Working closely with the Johan Lundin, Research Director
clinic, they aim for translation of basic research findings to
patient care. The group develops and studies digital diagnostic meth-
ods and AI for medical purposes with a goal to make new
Precision Systems Medicine medical discoveries, create solutions that perform beyond
Olli Kallioniemi, Research Director, Professor human expert capability and to improve access to diag-
nostics.
The group applies a functional systems medicine strategy,
which combines genomic and deep molecular profiling Epigenetics of Complex Diseases & Traits
with direct testing of efficacies of drugs in patient-derived Miina Ollikainen, Academy Research Fellow
cells, to the study of haematological cancers and solid
tumours, including urological and ovarian cancer. The group focuses on understanding the roles of genet-
ics and environment in epigenetic processes, and how
they relate to the development of common diseases and
complex traits, using study designs suitable for twin and
population-based cohorts.
16 | FIMM – Building a Bridge from Discovery to Medicine
